


Correction to Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12, 13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4*H*-indazolo[5,4-*a*]pyrrolo[3,4-*c*]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent

Robert L. Hudkins,* Nadine C. Becknell, Allison L. Zulli, Ted L. Underiner, Thelma S. Angeles, Lisa D. Aimone, Mark S. Albom, Hong Chang, Sheila J. Miknyoczki, Kathryn Hunter, Susan Jones-Bolin, Hugh Zhao, Edward R. Bacon, John P. Mallamo, Mark A. Ator, and Bruce A. Ruggeri*

Journal of Medicinal Chemistry 2012, 55, 903–913. DOI: 10.1021/jm201449n

Page 903. The structure of compound 4 in Figure 1 is brivanib alaninate (BMS582664) and should contain a methyl at the indole 2-position. The correct structure is shown below.



4 Brivanib alaninate